ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for a total enterprise value of $12 million USD. AVS Bio, a portfolio company of Arlington Capital Partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries.
Orrick represented IPA.
ImmunoPrecise Antibodies Ltd. is a biotherapeutics company focused on the discovery and development of next-generation biologics. The company combines scientific expertise with proprietary technologies—such as its LENSai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research.
This transaction marks a meaningful step in IPA’s strategic refinement—streamlining its operational footprint, strengthening its balance sheet, and allowing the company to concentrate resources on its most impactful growth areas. The proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.